{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:21:07Z","timestamp":1794493267025,"version":"4.9.1"},"reference-count":110,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are several classes of dissimilar antidepressant drugs approved for MDD, the current drugs have either limited efficacy or are associated with undesirable side effects and withdrawal symptoms. The efficacy and side effects of antidepressant drugs are mainly attributed to their actions on different monoamine neurotransmitters (serotonin, norepinephrine, and dopamine). Development of new antidepressants with novel targets beyond the monoamine pathways may fill the unmet need in treatment of MDD and TRD. The recent approval of intranasal Esketamine (glutamatergic agent) in conjunction with an oral antidepressant for the treatment of adult TRD patients was the first step toward expanding beyond the monoamine targets. Several other glutamatergic (AXS-05, REL-1017, AV-101, SLS-002, AGN24175, and PCN-101) and GABAergic (brexanolone, zuranolone, and ganaxolone) drugs are currently in different stages of clinical development for MDD, TRD and other indications. The renaissance of psychedelic drugs and the emergence of preliminary positive clinical trial results with psilocybin, Ayahuasca, 5-methoxy-<jats:italic>N,N<\/jats:italic>-dimethyltryptamine (5-MeO-DMT), and lysergic acid diethylamide (LSD) may pave the way towards establishing this class of drugs as effective therapies for MDD, TRD and other neuropsychiatric disorders. Going beyond the monoamine targets appears to be an effective strategy to develop novel antidepressant drugs with superior efficacy, safety, and tolerability for the improved treatment of MDD and TRD.<\/jats:p>","DOI":"10.1017\/s1092852921000791","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T09:34:23Z","timestamp":1632994463000},"page":"6-15","source":"Crossref","is-referenced-by-count":76,"title":["Novel antidepressant drugs: Beyond monoamine targets"],"prefix":"10.1017","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-4203","authenticated-orcid":false,"given":"Xenia","family":"Gonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-9378","authenticated-orcid":false,"given":"Frank I.","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"S1092852921000791_r74","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.03.004"},{"key":"S1092852921000791_r105","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113"},{"key":"S1092852921000791_r14","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0803"},{"key":"S1092852921000791_r49","unstructured":"49. Axsome Therpaeutics Press Release. Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who have suicidal Ideation; December 8, 2020."},{"key":"S1092852921000791_r55","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.225664"},{"key":"S1092852921000791_r44","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891"},{"key":"S1092852921000791_r26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4050"},{"key":"S1092852921000791_r15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1015"},{"key":"S1092852921000791_r68","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.11.1043"},{"key":"S1092852921000791_r89","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12887"},{"key":"S1092852921000791_r12","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30015-9"},{"key":"S1092852921000791_r97","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112749"},{"key":"S1092852921000791_r78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.08.012"},{"key":"S1092852921000791_r71","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.4.663"},{"key":"S1092852921000791_r85","unstructured":"85. Sage Therapeutics Press Release. Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder; December 5, 2019."},{"key":"S1092852921000791_r51","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001035"},{"key":"S1092852921000791_r45","first-page":"340","article-title":"Intranasal esketamine (Spravato\u2122) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"44","author":"Bahr","year":"2019","journal-title":"P T"},{"key":"S1092852921000791_r65","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-020-01110-5"},{"key":"S1092852921000791_r10","first-page":"429","volume-title":"Goodman and Gilman\u2019s: The Pharmacological Basis of Therapeutics","author":"Baldessarini","year":"2005"},{"key":"S1092852921000791_r38","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16010037"},{"key":"S1092852921000791_r59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.09.004"},{"key":"S1092852921000791_r61","unstructured":"61. Allergan Press Release. Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD); March 6, 2019."},{"key":"S1092852921000791_r102","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718001356"},{"key":"S1092852921000791_r109","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900625"},{"key":"S1092852921000791_r60","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000462606.17725.93"},{"key":"S1092852921000791_r21","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.96"},{"key":"S1092852921000791_r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"S1092852921000791_r73","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.150223"},{"key":"S1092852921000791_r106","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00943"},{"key":"S1092852921000791_r37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012414"},{"key":"S1092852921000791_r3","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"S1092852921000791_r110","doi-asserted-by":"publisher","DOI":"10.1177\/2045125321997293"},{"key":"S1092852921000791_r47","unstructured":"47. Axsome Therpaeutics Press Release. AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder; January 7, 2019."},{"key":"S1092852921000791_r58","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.246"},{"key":"S1092852921000791_r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"S1092852921000791_r62","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00882-7"},{"key":"S1092852921000791_r52","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)13391-2"},{"key":"S1092852921000791_r83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1403285111"},{"key":"S1092852921000791_r93","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0324-9"},{"key":"S1092852921000791_r101","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000436"},{"key":"S1092852921000791_r67","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R112.386664"},{"key":"S1092852921000791_r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.03.026"},{"key":"S1092852921000791_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2004.12.007"},{"key":"S1092852921000791_r5","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0309"},{"key":"S1092852921000791_r36","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1683161"},{"key":"S1092852921000791_r41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17060720"},{"key":"S1092852921000791_r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.03.026"},{"key":"S1092852921000791_r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.03.017"},{"key":"S1092852921000791_r27","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.255"},{"key":"S1092852921000791_r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"S1092852921000791_r76","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2017.02.012"},{"key":"S1092852921000791_r103","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2018.1545024"},{"key":"S1092852921000791_r20","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.20801"},{"key":"S1092852921000791_r56","unstructured":"56. VistaGen Therapeutics Press Release. VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder; November 14, 2019."},{"key":"S1092852921000791_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.12.010"},{"key":"S1092852921000791_r50","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0501-x"},{"key":"S1092852921000791_r77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.3239"},{"key":"S1092852921000791_r28","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0624-1"},{"key":"S1092852921000791_r24","doi-asserted-by":"publisher","DOI":"10.1080\/13811118.2019.1635930"},{"key":"S1092852921000791_r29","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0644-9"},{"key":"S1092852921000791_r72","doi-asserted-by":"publisher","DOI":"10.1097\/YCT.0b013e31815cbaa1"},{"key":"S1092852921000791_r84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815981"},{"key":"S1092852921000791_r86","unstructured":"86. Sage Therapeutics and Biogen Press Release. Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder; June 15, 2021."},{"key":"S1092852921000791_r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.0164"},{"key":"S1092852921000791_r64","unstructured":"64. Perception Neuroscience Press Release. Perception Neuroscience\u2019s PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study; February 19, 2021."},{"key":"S1092852921000791_r53","unstructured":"53. Relmada Therpaeutics Press Release. Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression; October 15, 2019."},{"key":"S1092852921000791_r96","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01011-0"},{"key":"S1092852921000791_r69","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145707007924"},{"key":"S1092852921000791_r99","first-page":"e203285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"S1092852921000791_r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.01.016"},{"key":"S1092852921000791_r23","doi-asserted-by":"publisher","DOI":"10.2174\/1568026620666200131100316"},{"key":"S1092852921000791_r1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2"},{"key":"S1092852921000791_r54","unstructured":"54. Relmada Therpaeutics Press Release. Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder; April 1, 2021."},{"key":"S1092852921000791_r81","unstructured":"81. FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-post-partum-depression. March 19, 2019."},{"key":"S1092852921000791_r92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.020"},{"key":"S1092852921000791_r100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"S1092852921000791_r104","doi-asserted-by":"publisher","DOI":"10.1159\/000467984"},{"key":"S1092852921000791_r107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.07.076"},{"key":"S1092852921000791_r34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17040472"},{"key":"S1092852921000791_r75","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.09.003"},{"key":"S1092852921000791_r87","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00605-7"},{"key":"S1092852921000791_r19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301312"},{"key":"S1092852921000791_r31","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"S1092852921000791_r2","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2020.1779308"},{"key":"S1092852921000791_r42","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"S1092852921000791_r8","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711000083"},{"key":"S1092852921000791_r22","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12902"},{"key":"S1092852921000791_r70","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.120"},{"key":"S1092852921000791_r79","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2576"},{"key":"S1092852921000791_r91","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2171"},{"key":"S1092852921000791_r4","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70283-5"},{"key":"S1092852921000791_r35","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy094"},{"key":"S1092852921000791_r48","unstructured":"48. Axsome Therpaeutics Press Release. Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder; December 16, 2019."},{"key":"S1092852921000791_r30","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18020138"},{"key":"S1092852921000791_r32","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"S1092852921000791_r66","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7696(02)13011-7"},{"key":"S1092852921000791_r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.07.036"},{"key":"S1092852921000791_r80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31551-4"},{"key":"S1092852921000791_r82","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333"},{"key":"S1092852921000791_r13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0712"},{"key":"S1092852921000791_r90","unstructured":"90. Marinus Pharmaceuticals Press Release. Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression; July 23, 2019."},{"key":"S1092852921000791_r94","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-020-0367-2"},{"key":"S1092852921000791_r95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13282-7"},{"key":"S1092852921000791_r9","first-page":"S353","article-title":"Current perspectives on the diagnosis and treatment of major depressive disorder","volume":"7","author":"Nierenberg","year":"2001","journal-title":"Am J Manag Care"},{"key":"S1092852921000791_r98","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"S1092852921000791_r18","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2462"},{"key":"S1092852921000791_r63","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136"},{"key":"S1092852921000791_r88","first-page":"1284","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852921000791_r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2013.10.002"},{"key":"S1092852921000791_r108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.02.011"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852921000791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T03:26:58Z","timestamp":1677036418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852921000791\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1092852921000791"],"URL":"https:\/\/doi.org\/10.1017\/s1092852921000791","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}